We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA warned Chinese API manufacturer Changzhou Jintan Qianyao Pharmaceutical Raw Materials for inadequate quality management and record-keeping. Read More
FDA inspectors found extensive cleanliness and sterility issues during visits to California Pharmacy and Compounding Center in Newport Beach, Calif., in March and April. Read More
The FDA issued a warning to an Oklahoma drug manufacturer after inspectors found significant GMP violations, including a lack of product testing. Read More
The FDA warned Chinese API manufacturer Changzhou Jintan Qianyao Pharmaceutical Raw Materials for inadequate quality management and record-keeping. Read More
The FDA warned Chinese API manufacturer Changzhou Jintan Qianyao Pharmaceutical Raw Materials for inadequate quality management and record-keeping. Read More
The FDA has warned that water systems used by manufacturers of non-sterile, water-based drugs are at risk of contamination from Burkholderia cepacia, a pathogen resistant to a wide range of antimicrobials. Read More